文献速递淋巴瘤

间变性大细胞淋巴瘤中替代性NF-κB通路激活的新型模型

A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.
PubMed 文献 · Leukemia · 2020-11-12

本研究在ALCL细胞系中发现NFKB2和NIK通路具有支持作用,通过CRISPR筛选和RNA-seq鉴定STAT3为NIK依赖NF-κB激活的主要介质。在NIK阳性ALK阴性ALCL中,JAK/STAT3突变促进STAT3转录活性并直接调控NFKB2和CD30表达,CD30通过结合并降解TRAF3诱导NF-κB持续激活。研究提示NIK和JAK联合抑制剂可能使携带JAK/STAT3体细胞突变的NIK阳性ALK阴性ALCL患者获益。

要点

  • STAT3是ALCL中NIK依赖NF-κB激活的主要介质
  • NIK阳性ALK阴性ALCL中JAK/STAT3突变驱动NFKB2和CD30表达
  • CD30通过结合并降解TRAF3诱导NF-κB持续激活

核心结论

  • 在ALCL中鉴定出STAT3介导NIK依赖的替代性NF-κB激活,且p-STAT3水平与NFKB2核积累相关。
  • NIK阳性ALK阴性ALCL中JAK/STAT3突变通过STAT3直接调控NFKB2和CD30,CD30降解TRAF3诱导NF-κB激活。
  • ALK阳性ALCL中NPM-ALK阻断CD30通路,但仍可诱导STAT3活性和NFKB2表达,导致 minimal 替代性NF-κB激活。

研究设计与样本

  • 使用ALCL细胞系模型进行替代性NF-κB报告基因CRISPR筛选,随后进行RNA-seq分析。
  • 在原发性临床样本中检测p-STAT3水平与NFKB2核积累的相关性。

主要发现

  • NFKB2和NIK通路在一些ALCL细胞系中具有支持作用。
  • CRISPR筛选和RNA-seq鉴定STAT3为NIK依赖NF-κB激活的主要介质。
  • p-STAT3水平与原发性临床样本中NFKB2核积累相关。
  • 在NIK阳性ALK阴性ALCL细胞中,常见JAK/STAT3突变促进STAT3转录活性,直接调控NFKB2和CD30表达。
  • 内源性CD30通过结合并降解TRAF3诱导 constitutively NF-κB激活;在ALK阳性ALCL中CD30通路被NPM-ALK阻断,但仍可诱导STAT3活性和NFKB2表达,导致 minimal 替代性NF-κB激活。

临床怎么用

  • NIK和JAK联合抑制剂治疗可能使携带JAK/STAT3体细胞突变的NIK阳性ALK阴性ALCL患者获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant activation of NF-κB is the most striking oncogenic mechanism in B-cell lymphoma; however, its role in anaplastic large cell lymphomas (ALCL) has not been fully established and its activation mechanism(s) remain unclear. Using ALCL cell line models, we revealed the supporting roles for NFKB2 and the NIK pathway in some ALCL lines. To investigate the detailed activation mechanisms for this oncogenic pathway, we performed specifically designed alternative NF-κB reporter CRISPR screens followed by the RNA-seq analysis, which led us to identify STAT3 as the major mediator for NIK-dependent NF-κB activation in ALCL. Consistently, p-STAT3 level was correlated with NFKB2 nuclear accumulation in primary clinical samples. Mechanistically, we found that in NIK-positive ALK- ALCL cells, common JAK/STAT3 mutations promote transcriptional activity of STAT3 which directly regulates NFKB2 and CD30 expression. Endogenous expression of CD30 induces constitutive NF-κB activation through binding and degrading of TRAF3. In ALK+ ALCL, the CD30 pathway is blocked by the NPM-ALK oncoprotein, but STAT3 activity and resultant NFKB2 expression can still be induced by NPM-ALK, leading to minimal alternative NF-κB activation. Our data suggest combined NIK and JAK inhibitor therapy could benefit patients with NIK-positive ALK- ALCL carrying JAK/STAT3 somatic mutations.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang H, Wei W, Zhang JP, et al. A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma. Leukemia. 2020. PMID: 33184494. doi:10.1038/s41375-020-01088-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。